Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma

Haematologica

Volumn 95, Issue 11, 2010, Pages 1865-1872

  Baran Marszak, Fanny ^a,b,c   Boukhiar, Mohand ^a,b   Harel, Stéphanie ^c   Laguillier, Christelle ^c   Roger, Claudine ^a,b,c   Gressin, Remy ^a,d,e,f   Martin, Antoine ^a,b,c,d,e,f   Fagard, Remi ^a,b   Varin Blank, Nadine ^a,b   Ajchenbaum Cymbalista, Florence ^a,b,c   Ledoux, Dominique ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c AVICENNE HOSPITAL   (France)

^d UNIV GRENOBLE ALPES   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f French GOELAMS Group

Author keywords

B cell receptor; Bortezomib; Mantle cell lymphoma; STAT3

Indexed keywords

B LYMPHOCYTE RECEPTOR; BORTEZOMIB; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE; STAT3 PROTEIN;

ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ISOLATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 78149266421     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.019745     Document Type: Article

References (35)

1. Zelenetz AD. Mantle cell lymphoma: an update on management. Ann Oncol. 2006;17 (Suppl 4):iv 12-4.
2. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867-74.
3. Camacho FI, Algara P, Rodriguez A, Ruiz-Ballesteros E, Mollejo M, Martinez N, et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood. 2003;101(10):4042-6.
4. Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res. 2003; 63(23):8226-32.
5. Lai R, Rassidakis GZ, Medeiros LJ, Leventaki V, Keating M, McDonnell TJ. Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours. J Pathol. 2003;199(1):84-9.
6. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nature reviews 2004;4(2):97-105.
7. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11): 798-809.
8. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA. 2007;104(18): 7391-6.
9. Visser HP, Tewis M, Willemze R, Kluin-Nelemans JC. Mantle cell lymphoma proliferates upon IL-10 in the CD40 system. Leukemia. 2000;14(8):1483-9.
10. Karras JG, Wang Z, Huo L, Howard RG, Frank DA, Rothstein TL. Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, selfrenewing B-1 cells but only inducibly expressed in conventional B lymphocytes. J Exp Med. 1997;185(6):1035-42.
11. Fan H, Rothstein TL. Lymphokine dependence of STAT3 activation produced by surface immunoglobulin cross-linking and by phorbol ester plus calcium ionophore treatment in B cells. Eur J Immunol. 2001;31(2): 665-71.
12. Wang L, Kurosaki T, Corey SJ. Engagement of the B-cell antigen receptor activates STAT through Lyn in a Jak-independent pathway. Oncogene. 2007;26(20):2851-9.
13. Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood. 2002;100(13):4537-43.
14. Casola S, Otipoby KL, Alimzhanov M, Humme S, Uyttersprot N, Kutok JL, et al. B cell receptor signal strength determines B cell fate. Nat Immunol. 2004;5(3):317-27.
15. Deglesne PA, Chevallier N, Letestu R, Baran-Marszak F, Beitar T, Salanoubat C, et al. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. Cancer Res. 2006;66(14): 7158-66.
16. Belessi CJ, Davi FB, Stamatopoulos KE, Degano M, Andreou TM, Moreno C, et al. IGHV gene insertions and deletions in chronic lymphocytic leukemia: CLLbiased deletions in a subset of cases with stereotyped receptors. Eur J Immunol. 2006;36(7):1963-74.
17. Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006;13(11):1235-42.
18. Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007;18(1):116-21.
19. Gressin R, Caulet Maugendre S, Le Gouill S, Ojeda Uribe M, Alexis Vigier M, Bouabdallah K, et al. Interim results of the RiPAD+C regimen including velcade in front line therapy for elderly patients with mantle cell lymphoma. A phase II prospective study of the GOELAMS group. Blood. (ASH Annual Meeting Abstracts) 2008;112:1575.
20. Goy A. New directions in the treatment of mantle cell lymphoma: an overview. Clin Lymphoma Myeloma. 2006;7 (Suppl 1): S24-32.
21. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NFkappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171(1):88-95.
22. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kappa;B pathways in subtypes of diffuse large Bcell lymphoma. Blood. 2008;111(7):3701-13.
23. Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 2004;23(20):3530-40.
24. Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr, Gutkind JS. Molecular crosstalk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia. 2006;8(9): 733-46.
25. Dai Y, Rahmani M, Pei XY, Dent P, Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood. 2004;104(2):509-18.
26. Lai R, Lefresne SV, Franko B, Hui D, Mirza I, Mansoor A, et al. Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome. Mod Pathol. 2006;19(11):1498-505.
27. Kienle D, Krober A, Katzenberger T, Ott G, Leupolt E, Barth TF, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood. 2003;102(8): 3003-9.
28. Letestu R, Ugo V, Valensi F, Radford-Weiss I, Nataf J, Levy V, et al. Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders. Leukemia. 2004;18(5):953-61.
29. Thorselius M, Walsh S, Eriksson I, Thunberg U, Johnson A, Backlin C, et al. Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. Eur J Haematol. 2002;68(4):217-24.
30. Walsh SH, Thorselius M, Johnson A, Soderberg O, Jerkeman M, Bjorck E, et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood. 2003;101(10):4047-54.
31. Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12): 4975-81.
32. Mizuno T, Rothstein TL. B cell receptor (BCR) cross-talk: CD40 engagement creates an alternate pathway for BCR signaling that activates I kappa B kinase/I kappa B alpha/NF-kappa B without the need for PI3K and phospholipase C gamma. J Immunol. 2005;174(10):6062-70.
33. Su L, Rickert RC, David M. Rapid STAT phosphorylation via the B cell receptor. Modulatory role of CD19. J Biol Chem. 1999;274(45):31770-4.
34. Otero DC, Poli V, David M, Rickert RC. Cutting edge: inherent and acquired resistance to radiation-induced apoptosis in B cells: a pivotal role for STAT3. J Immunol. 2006;177(10):6593-7.
35. Karras JG, Huo L, Wang Z, Frank DA, Zimmet JM, Rothstein TL. Delayed tyrosine phosphorylation and nuclear expression of STAT1 following antigen receptor stimulation of B lymphocytes. J Immunol. 1996;157(6):2299-309.